Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.58 |
| ▸ | F12 | P00748 | 1/20 | 0.58 |
| ▸ | PLAU | P00749 | 1/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.54 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.52 |
| ▸ | KDM4A | O75164 | 1/20 | 0.52 |
| ▸ | KDM4B | O94953 | 1/20 | 0.52 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20641503 | 1.00 | F2 (0.58) | F2F12PLAUADORA1ADORA2A | |
| SCHEMBL29743862 | 0.93 | TRPV1 (0.52) | F2F12PLAUADORA1ADORA2A | |
| SCHEMBL23406002 | 0.93 | TRPV1 (0.52) | F2F12PLAUADORA1ADORA2A | |
| SCHEMBL29744058 | 0.90 | GRM1 (0.57) | F2F12PLAUPTPN1TRPV1 | |
| SCHEMBL23406009 | 0.90 | GRM1 (0.57) | F2F12PLAUPTPN1TRPV1 | |
| SCHEMBL23405923 | 0.90 | ADORA3 (0.57) | ADORA3TRPV1NPC1RAB9AMEN1 | |
| SCHEMBL29743831 | 0.90 | ADORA3 (0.57) | ADORA3TRPV1NPC1RAB9AMEN1 | |
| SCHEMBL23406076 | 0.88 | CYP2A6 (0.55) | NPC1RAB9AMEN1KMT2A | |
| SCHEMBL29743805 | 0.88 | CYP2A6 (0.55) | NPC1RAB9AMEN1KMT2A | |
| SCHEMBL23406114 | 0.88 | GRM5 (0.54) | NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11377436-B2 | EAAT2 enhancing molecules | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2022-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11377436-B2 | EAAT2 enhancing molecules | SLC1A2, SLC1A1, SLC1A3 | F2 4851/4885F12 4876/4885PLAU 3312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.